Skip to main content
. Author manuscript; available in PMC: 2015 Oct 19.
Published in final edited form as: J Pharm Sci. 2009 Aug;98(8):2731–2746. doi: 10.1002/jps.21630

Table V.

Cascade impaction results of lyophilized budesonide nanoparticle agglomerates (values = average ± S.D.).

Characteristics of the lyophilized NAd Formulations
F1a F2b F3c
At flow rate of ~15 L//min % EFe 74.9 ± 6.1 69.3 ± 5.5 86.5 ± 8.6
% RFf < 5.7 96.3 ± 1.8 97.5 ± 1.3 97.9 ± 0.3
< 3.3 77.6 ± 3.9 81.2 ± 5.2 75.3 ± 1.7
MMADg 1.7 ± 0.1 1.5 ± 0.1 1.9 ± 0.3
GSDh 2.4 ± 0.2 2.3 ± 0.1 2.3 ± 0.3
At flow rate of ~30 L//min % EFe 75.3 ± 7.3 70.2 ± 4.1 81.2 ± 12.9
% RFf < 5.7 97.1 ± 0.2 96.8 ± 1.5 96.9 ± 1.4
< 3.3 84.3 ± 3.9 87.7 ± 1.5 82.3 ± 4.2
MMADg 1.3 ± 0.2 1.2 ± 0.04 1.6 ± 0.3
GSDh 2.3 ± 0.3 2.3 ± 0.4 2.3 ± 0.1
At flow rate of ~60 L//min % EFe 77.4 ± 6.6 72.2 ± 5.9 82.9 ± 12.7
% RFf < 5.7 95.8 ± 0.2 95.9 ± 1.5 95.7 ± 1.7
< 3.3 87.1 ± 2.3 89.3 ± 2.5 83.6 ± 2.8
MMADg 1.1± 0.2 1.1 ± 0.1 1.3 ± 0.2
GSDh 2.3 ± 0.1 2.3 ± 0.2 2.3 ± 0.1
a

F1 = 0.1: 0.02; Bud: Lec

b

F2 = 0.1: 0.02: 0.01; Bud: CA: PL

c

F3 = 0.2: 0.04: 0.02; Bud: CA: PL

d

NA: Nanoparticle agglomerates.

e

% EF: Percent emitted fraction.

f

RF: Percent respirable fraction.

g

MMAD: Mass median aerodynamic diameter.

h

GSD: Geometric standard deviation.